Archive for March, 2010

Former Drug Rep – Kathleen Slattery-Moschkau.

Tuesday, March 30th, 2010

KATHLEEN SLATTERY-MOSCHKAU:  mom, wife, and former legal drug pusher turned filmmaker. She wrote, directed, and co-produced the independent feature film Side Effects (starring Katherine Heigl) as well as the documentary Money Talks: Profits Before Patient Safety. After college, Kathleen spent a decade working for the pharmaceutical industry as a drug sales representative. During her tenure as a drug rep she sold fluoroquinolone antibiotics. The company she worked for marketed fluoroquinolones as a first line antibiotic, instead of reserving them for a last line of defense.

 Her film, Money Talks: Profits Before Patient Safety was deemed by the American Library Association as one of the most important films of 2008. Kathleen also hosts a weekly radio show, The Kathleen Show focusing on issues surrounding life, health, and entertainment. You can view Money Talks documentary below along with her website.

www.TheKathleenShow.com   AND   www.MoneyTalksTheMovie.com


Story of father and son injured from Flagyl and Cipro.

Saturday, March 27th, 2010

My son had neurological damage ( long term from 6 weeks of Flagyl as a 3 year old.) Like falling all the time, no balance, vision damage, speech therapy needed for 4 years.

Never would have thought an antibiotic could do this until Cipro blew out my tendon behind my knee. Then the Diabetes Insipidus set in…mild. In 2007 I took a week of Flagyl,,, which kicked it all in bad. When I fell all the time, and I could not speak,,,I suddenly knew what had happened to my son!

 I laughed when someone told me 3-5 years for recovery…well it has been 2 and 1/2. Hyperacusis,,,never knew what that was,,till a week of Flagyl.

 I wish I had that case of diarrhea from Mexico back !

Johnson and Johnson sued the Red Cross.

Thursday, March 25th, 2010

Here is an old story about Johnson and Johnson bringing legal action against the Red Cross. Johnson and Johnson sued a charitable organization. It doesn’t get much lower than this.   

http://www.usatoday.com/money/companies/2007-08-08-redcross-lawsuit_N.htm

Frequency of pharmaceutical sales rep visits to doctor’s offices.

Sunday, March 21st, 2010

How Many Reps Visit A Doctor’s Office Each Week?

52 CommentsBy Ed Silverman // March 11th, 2010 // 9:18 am

sales-repIf you guessed 20, you win a free drug company tchotchka. A recent survey found that 98 percent of physicians reported that their offices received 20 or less visits each week by sales reps, while 37 percent reported only one visit per week. This would suggest that the industry push to roll back the onslaught of visits hasn’t taken hold, although the survey, which was conducted by SK&A, doesn’t offer a breakdown on the types of meds or reps involved (register here).

Here’s another interesting finding: 73.4 percent of physicians reported their offices granted access to reps in December 2008, and that rose to 77.1 percent in December 2009. In other words, the proportion of physician offices barring access fell, which would suggest a notable reversal. However, one datapoint is in keeping with collective industry assumptions – more appointments are being required. This rose from 38.5 percent of offices in late 2008 to 49.6 percent in late 2009.

Report of Akathisia from Cipro – Dr. Jay Cohen

Friday, March 12th, 2010

Never heard of Akathisia before. Apparently Dr. Cohen is familiar with this condition. Here is his latest report regarding Cipro and Akathisia.

http://www.medicationsense.com/articles/2010/ciproakathisia0210.html

 

Drug Industry Executives.

Saturday, March 6th, 2010

FDA May Prosecute More Pharmaceutical Execs.

37 Comments

jailThe FDA plans to increase misdemeanor prosecutions of industry execs as it looks to refocus its Office of Criminal Investigations (see this letter to the Senate Finance committee). The move comes in response to a new report from the General Accountability Office that the OCI suffers from lax oversight, despite increased in funding and staffing over the past decade. In fact, the FDA hasn’t reviewed most OCI offices in more than three years. The OCI investigates counterfeit drugs and other bad stuff, as well as misconduct by FDA employees.

The GAO concluded the FDA “has relied largely on the OCI director to determine which aspects of OCI’s operations and investigations are made known to FDA’s top management.” The GAO found assessments of six OCI field offices aren’t being done on a timely basis. Of 24 total office assessments that should have been completed by August 2009, only 7, or about 30 percent, were completed and one office hadn’t been assessed in over 10 years.

In addition, the FDA lacks performance measures that could enhance oversight by allowing it to assess OCI’s overall success. A few more facts: the OCI has a 230-person operation with more than $41 million in funding. In 2008, the group’s investigations led to more than 400 convictions. The OCI budget rose 73 percent between 1999 and 2008 to $41 million, and the number of employees increased by about 40 percent.

The GAO study, which was first reported by The Wall Street Journal, was requested by Chuck Grassley, the ranking Republican on the US Senate Finance, who has been probing drug safety issues, among other things. A report on GlaxoSmithKline’s Avandia noted that several drugmakers – Pfizer, Lilly, Bristol-Myers Squibb – have recently paid large criminal fines totaling $7 billion. Among the infractions – off-label promotion. This is not the first time Congress has leaned on the FDA’s COI (see here and here), and the Senate report continued to do so by concluding that “such an environment requires diligent oversight by the FDA to protect the citizens of this country and to ensure the safety of American medicine.”

Maybe criminal defense lawyers will be in vogue?